CAM Group Holding A S held its position in Flex Pharma Inc. (NASDAQ:FLKS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 150,000 shares of the biotechnology company’s stock at the end of the second quarter. CAM Group Holding A S’s holdings in Flex Pharma were worth $1,532,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Strs Ohio boosted its position in Flex Pharma by 444.4% in the second quarter. Strs Ohio now owns 9,800 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 8,000 shares during the period. Acadian Asset Management LLC purchased a new position in Flex Pharma during the second quarter valued at approximately $114,000. State Street Corp boosted its position in Flex Pharma by 24.1% in the first quarter. State Street Corp now owns 51,490 shares of the biotechnology company’s stock valued at $566,000 after buying an additional 9,990 shares during the period. JPMorgan Chase & Co. boosted its position in Flex Pharma by 25.5% in the first quarter. JPMorgan Chase & Co. now owns 283,682 shares of the biotechnology company’s stock valued at $3,112,000 after buying an additional 57,729 shares during the period. Finally, Primecap Management Co. CA boosted its position in Flex Pharma by 44.5% in the first quarter. Primecap Management Co. CA now owns 634,721 shares of the biotechnology company’s stock valued at $6,963,000 after buying an additional 195,346 shares during the period. 33.74% of the stock is owned by institutional investors and hedge funds.
Flex Pharma Inc. (NASDAQ:FLKS) traded down 1.83% during midday trading on Wednesday, reaching $6.43. The company had a trading volume of 75,928 shares. The stock’s 50 day moving average is $10.89 and its 200 day moving average is $11.29. The company’s market capitalization is $101.38 million. Flex Pharma Inc. has a one year low of $6.35 and a one year high of $13.97.
Flex Pharma (NASDAQ:FLKS) last posted its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.04. The company earned $12.69 million during the quarter. Equities research analysts forecast that Flex Pharma Inc. will post ($2.67) earnings per share for the current fiscal year.
Several equities analysts have commented on the company. Zacks Investment Research raised Flex Pharma from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Flex Pharma in a research note on Saturday. Cantor Fitzgerald lowered Flex Pharma from a “buy” rating to a “hold” rating and lowered their price objective for the company from $22.00 to $10.00 in a research note on Friday, October 14th. Finally, Piper Jaffray Cos. set a $25.00 price objective on Flex Pharma and gave the company a “buy” rating in a research note on Thursday, August 18th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.88.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Want to see what other hedge funds are holding FLKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flex Pharma Inc. (NASDAQ:FLKS).
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.